Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

CAN-Scan: a multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer

ABSTRACT: CAN-Scan: a multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer

PROVIDER: PRJNA1215353 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR32113100_1.fastq.gz	Fastqsanger.gz
	SRR32113100_2.fastq.gz	Fastqsanger.gz
	SRR32113101_1.fastq.gz	Fastqsanger.gz
	SRR32113101_2.fastq.gz	Fastqsanger.gz
	SRR32113102_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 138

Similar Datasets

CAN-Scan: a multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer

Project description:Application of machine learning (ML) on cancer-specific pharmacogenomic datasets shows immense promise for identifying predictive response-biomarkers to enable personalized treatment. We introduce CAN-Scan, a precision oncology platform, that applies ML on next-generation pharmacogenomic datasets generated from a freeze-viable biobank of patient-derived primary cell lines (PDCs). These PDCs are screened against 84 FDA-approved drugs at clinically relevant doses (Cmax), focusing on colorectal cancer (CRC) as a model system. CAN-Scan uncovers prognostic biomarkers and alternative treatment strategies, particularly for patients unresponsive to first-line chemotherapy. Specifically, it identifies gene expression signatures linked to resistance against 5-Fluorouracil (5FU)-based drugs and a focal copy number gain on chromosome 7q, harbouring critical resistance-associated genes. CAN-Scan-derived response signatures accurately predict clinical outcomes across four independent, ethnically-diverse CRC cohorts. Notably, drug-specific ML models reveal Regorafenib and Vemurafenib as alternative treatments for BRAF-expressing, 5FU-insensitive CRC. Altogether, this approach demonstrates significant potential in improving biomarker-discovery and guiding personalized treatments.

2025-04-04 | GSE287956 | GEO

Patient-derived micro-organospheres (MOS) enable clinical precision oncology

Project description:Patient-derived xenografts (PDX) and organoids (PDO) have been shown to model clinical response to cancer therapy. However, it remains challenging to use these models to guide timely clinical decisions for cancer patients. Here we used droplet emulsion microfluidics with temperature control and dead-volume minimization to rapidly generate thousands of Micro- Organospheres (MOS) from low-volume patient tissues, which serve as an ideal patient-derived model for clinical precision oncology. A clinical study of newly diagnosed metastatic colorectal cancer (CRC) patients using a MOS-based precision oncology pipeline reliably predicted patient treatment outcome within 14 days, a timeline suitable for guiding treatment decisions in clinic. Furthermore, MOS capture original stromal cells and allow T cell penetration, providing a clinical assay for testing immuno-oncology (IO) therapies such as PD-1 blockade, bispecific antibodies, and T cell therapies on patient tumors.

2022-09-01 | GSE184242 | GEO

CPTAC: Microscaled Proteogenomic Methods for Precision Oncology

Project description:CPTAC: Microscaled Proteogenomic Methods for Precision Oncology

| PRJNA574689 | ENA

The OncoLoop Network-based Precision Oncology Framework

Project description:The OncoLoop Network-based Precision Oncology Framework

| PRJNA774549 | ENA

CPTAC: Microscaled Proteogenomic Methods for Precision Oncology

Project description:CPTAC: Microscaled Proteogenomic Methods for Precision Oncology

| PRJNA574688 | ENA

A Single-Cell Tumor Immune Atlas for Precision Oncology

Project description:The tumor immune microenvironment is a main contributor to cancer progression and a promising therapeutic target for oncology. However, immune microenvironments vary profoundly between patients and biomarkers for prognosis and treatment response lack precision. A comprehensive compendium of tumor immune cells is required to pinpoint predictive cellular states and their spatial localization. We generated a single-cell resolved tumor immune cell atlas, jointly analyzing >500,000 cells from 217 patients and 13 cancer types, providing the basis for a patient stratification based on immune cell compositions. Projecting immune cells from external tumors onto the atlas facilitated an automated cell annotation system for a harmonized interpretation. To enable in situ mapping of immune populations for digital pathology, we developed SPOTlight, a computational tool that identified striking spatial immune cell patterns in tumor sections. We expect the atlas, together with our versatile toolbox for precision oncology, to advance currently applied stratification strategies for prognosis and immuno-therapy response.

2020-10-27 | GSE158803 | GEO

Synthetic lethality-mediated precision oncology via the tumor transcriptome

Project description:Precision oncology has made significant advances in the last few years, mainly by targeting actionable mutations in cancer driver genes. However, the proportion of patients whose tumors can be targeted therapeutically remains limited. Recent studies have begun to explore the benefit of analyzing tumor transcriptomics data to guide patient treatment, raising the need for new approaches for systematically accomplishing that. Here we show that computationally derived genetic interactions can successfully predict patient response.

2021-02-11 | GSE166449 | GEO

Towards Optimization of Precision Oncology in Metastatic Uterine Tumors

Project description:Precision oncology and its diagnostic tools are essential for developing personalized cancer treatments. The purpose of this study was to integrate data on the digital patterns of reticulin fiber scaffolding and the immune cell infiltrate, transcriptomic and epigenetic profiles in aggressive uterine adenocarcinoma (uADC), uterine leiomyosarcoma (uLMS) and their respective lung metastases (LM-uADC and LM-uLMS), with the aim of obtaining key tumor microenvironment (TME) biomarkers that can help improve metastatic prediction and shed light on potential therapeutic targets.

2022-12-16 | GSE216313 | GEO

A Single-Cell Tumor Immune Atlas for Precision Oncology

Project description:A Single-Cell Tumor Immune Atlas for Precision Oncology

| PRJNA666613 | ENA

Towards Optimization of Precision Oncology in Metastatic Uterine Tumors

Project description:Towards Optimization of Precision Oncology in Metastatic Uterine Tumors

| PRJNA892975 | ENA